Braidwell
Braidwell reported 86 stocks worth $2.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KOD (4.4%), CAI (3.6%) and EWTX (3.6%). Compared with Q2 2026, the fund opened new positions in DMRA, NVCT and TEVA, added to EWTX, ATEC and XENE, trimmed KOD, CAI and IRTC and sold out of ACAD, CDNA and DYN.
Latest filing: what Braidwell did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() KOD Kodiak Sciences Inc | $103M | 4.4% | 1.1M | −702K (−39%) | 4 of 8 | |
| 2 | ![]() CAI Caris Life Sciences Inc | $84.1M | 3.6% | 2.7M | −5.5M (−67%) | 6 of 8 | |
| 3 | ![]() EWTX Edgewise Therapeutics Inc | $84M | 3.6% | 2.1M | +72K (+4%) | 8 of 8 | |
| 4 | ![]() ATEC Alphatec Hldgs Inc | $74.6M | 3.2% | 7.2M | +697K (+11%) | 7 of 8 | |
| 5 | ![]() IRTC Irhythm Technologies Inc | $72.8M | 3.1% | 641K | −14K (−2%) | 8 of 8 | |
| 6 | ![]() HNGE Hinge Health Inc | $63.7M | 2.7% | 655K | −675K (−51%) | 5 of 8 | |
| 7 | ![]() SYRE Spyre Therapeutics Inc | $63.6M | 2.7% | 714K | −166K (−19%) | 8 of 8 | |
| 8 | ![]() XENE Xenon Pharmaceuticals Inc | $63.5M | 2.7% | 1.7M | +577K (+51%) | 8 of 8 | |
| 9 | ![]() NEO Neogenomics Inc | $61.5M | 2.6% | 3.3M | −1.6M (−32%) | 5 of 8 | |
| 10 | ![]() GKOS Glaukos Corp | $56.5M | 2.4% | 344K | −248K (−42%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
GALECTO INC | $42.1M | 1.6M |
![]() ACAD Acadia Pharmaceuticals Inc | $41.7M | 1.6M |
![]() CDNA Caredx Inc | $34.8M | 1.2M |
![]() DYN Dyne Therapeutics Inc | $20.5M | 922K |
![]() ARGX Argenx SE | $16.4M | 18K |
🔒 Free account: see all 13.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Braidwell 13F FAQ
What does Braidwell own?
Braidwell reported 86 stocks worth $2.3B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KOD (4.4%), CAI (3.6%) and EWTX (3.6%). The table above lists every position in the filing (the top 10 without an account).
What did Braidwell buy and sell in Q3 2026?
Compared with Q2 2026: 16 new positions, 19 added to, 38 trimmed and 13 sold out. New positions include DMRA, NVCT and TEVA. It sold all of ACAD, CDNA and DYN.
When will Braidwell file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Braidwell's portfolio worth?
The Q3 2026 filing reports $2.3B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.























